Investor Updates

17. Juni 2013
Roche's Avastin approved in Japan for treatment of the most aggressive form of brain cancer
Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab) for ... mehr

14. Juni 2013
Anti-Cancer Agent, Herceptin Obtained Approval for Dosage and Administration for Postoperative Adjuvant Chemotherapy in Breast Cancer in Japan
Please find attached a press release by Chugai mehr

14. Juni 2013
Anti-Cancer Agent Tarceva, Obtained Approval for Additional Indication (First Line Therapy) of Non-Small Cell Lung Cancer with EGFR Mutations in Japan
Please find attached a press release by Chugai mehr

13. Juni 2013
Roche's RoACTEMRA shows long-term efficacy in monotherapy and also benefits in early rheumatoid arthritis
Roche today announced data from two phase III studies using RoACTEMRA (tocilizumab) in patients with rheumatoid arthritis ... mehr

10. Juni 2013
Roche's RoACTEMRA approved in EU to treat children with rare form of arthritis
Roche announced today that the European Medicines Agency has approved RoACTEMRA to treat children with polyarticular juvenile ... mehr

03. Juni 2013
Promising data from the Bcl-2 inhibitor GDC-0199/ABT-199 in hematology presented at ASCO
Late stage development underway in chronic lymphocytic leukemia. Roche today announced promising phase 1 data from a study ... mehr

02. Juni 2013
Roche's medicine Avastin plus chemotherapy improved survival in women with advanced cervical cancer, compared to chemotherapy alone
Roche today announced the results of a large, independent study (GOG240) sponsored by the US National Cancer Institute (NCI) ... mehr

01. Juni 2013
Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer
Roche today announced final results from the phase III AVAglio study in people with newly diagnosed glioblastoma, the most ... mehr

24. Mai 2013
Roche Analyst Event at ASCO 2013
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products ... mehr

24. Mai 2013
Launch of Subcutaneous Injection formulation, Actemra, for treatment of Rheumatoid Arthritis in Japan
mehr

22. Mai 2013
Roche presents new, fully automated lab solution at Europe's largest diagnostics conference
Roche announced today at the IFCC Euromedlab in Milan, Italy that it will soon introduce the cobas 8100 automated workflow ... mehr

18. Mai 2013
Roche's etrolizumab meets primary endpoint of clinical remission in moderate to severely active ulcerative colitis at week 10
Roche announced today that the EUCALYPTUS phase II induction study of etrolizumab in patients with moderate-to-severely active ... mehr

16. Mai 2013
Roche to present data on investigational cancer immunotherapy anti-PDL1 antibody MPDL3280A at ASCO 2013
Roche today announced that the company will present important new data on its anti-PDL1 antibody MPDL3280A (also known as ... mehr

16. Mai 2013
Roche's obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer
Roche today announced the first results from CLL11, a phase III study of the investigational medicine GA101 which is being ... mehr

15. Mai 2013
FDA approves Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer
Tarceva is the first personalised medicine approved for the initial treatment of people with EGFR mutation-positive advanced ... mehr

15. Mai 2013
Roche to present important new data reflecting broad cancer pipeline at ASCO
Roche today announced that important new data from clinical trials of several investigational and approved cancer medicines ... mehr

02. Mai 2013
Roche Analyst Event at ASCO 2013
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products ... mehr

30. April 2013
FDA approves ACTEMRA for children living with a rare form of arthritis
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved ACTEMRA (tocilizumab) for the treatment ... mehr

26. April 2013
CHMP recommends conditional EU approval of Roche's Erivedge for advanced basal cell carcinoma, a rare but potentially devastating form of skin cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended ... mehr

26. April 2013
Roche gains CHMP positive opinion for RoACTEMRA for children living with a rare form of arthritis in Europe
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ... mehr

23. April 2013
Roche to change Applied Science business structure
Roche today announced changes to the management and set-up of its life-science business. The Applied Science Business Area ... mehr

11. April 2013
Roche Group posts strong sales growth in the first quarter
Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven ... mehr

04. April 2013
Reminder: Invitation to Roche's First Quarter Sales 2013 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2013 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

25. März 2013
Actemra, a Treatment for Rheumatoid Arthritis Obtained Approval for Subcutaneous Injection Formulation
Dear Investor, Please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. mehr

21. März 2013
Roche adopts IAS19 (revised) and implements presentational changes with effect from 1 January 2013
Change in the accounting policy - IAS 19 (revised) Employee Benefits. Presentational change - Pharmaceuticals Division geographic ... mehr

18. März 2013
Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older
Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) ... mehr

11. März 2013
Invitation to Roche's First Quarter Sales 2013 Conference Call
Thursday April 11th, 2013 - 14:00 CEST. Roche will publish its Sales Results for the 1st Quarter of 2013 prior to the opening ... mehr

06. März 2013
FDA approves new Roche test to evaluate response to hepatitis C therapy
Viral load test uses a novel dual-probe approach designed to manage patients being treated with antiviral therapies. Roche ... mehr

05. März 2013
Roche Annual General Meeting 2013
Roche announced today that its Ordinary Annual General Meeting voted in favour of all the Board of Directors' proposals. ... mehr

05. März 2013
Roche Chairman Franz B. Humer announces that he will not stand for re-election in 2014
Franz B. Humer, Chairman of the Board of Directors of the Roche Group, announced at today’s Annual General Meeting that ... mehr

05. März 2013
Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously ... mehr

22. Februar 2013
FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (trastuzumab emtansine or T-DM1) ... mehr

18. Februar 2013
Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin for acromegaly and neuroendocrine tumors
Roche and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into ... mehr

31. Januar 2013
Obinutuzumab (GA101) significantly improved progression-free survival in people with chronic lymphocytic leukemia (CLL)
Roche today announced positive results from stage 1 of CLL11, a phase III randomised study to investigate the efficacy and ... mehr

30. Januar 2013
Full reconciliation of Chugai 2012 results into IFRS
Results of Chugai as consolidated by the Roche Group mehr

30. Januar 2013
Roche delivers strong 2012 results
Group sales rise 4% to 45.5 billion Swiss francs due to oncology sales, clinical laboratory business; Core EPS 10% higher ... mehr

29. Januar 2013
New Drug Application Filed for Antibody-Drug Conjugate
Trastuzumab Emtansine for the Treatment of HER2-Positive Metastatic or Recurrent Breast Cancer mehr

24. Januar 2013
FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination ... mehr

21. Januar 2013
Reminder: Invitation to Roche's Full Year Results for 2012
Roche will publish its Full Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 30 January 2013, 7:00 ... mehr

15. Januar 2013
Change to the Roche Corporate Executive Committee
Roche today announced that John C. Reed, M.D., Ph.D., has been appointed Head of Roche Pharma Research and Early Development ... mehr

02. Januar 2013
Invitation to Roche's Full Year Results for 2012
Roche will publish its Full Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 30 January 2013. mehr

21. Dezember 2012
Roche and PSS sign agreement to develop a fully automated workflow solution for next-generation sequencing platforms
Roche and Precision System Science, Co., Ltd today announced the signing of an exclusive agreement to develop and manufacture ... mehr

20. Dezember 2012
Roche's vismodegib named Drug Discovery of the Year by the British Pharmacological Society
Roche today announced that the first in class Hedgehog pathway inhibitor vismodegib, was named Drug Discovery of the Year ... mehr

14. Dezember 2012
Roche’s breast cancer treatment Perjeta receives recommendation for approval in EU
Roche gab heute bekannt, dass der EU-Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, ... mehr

11. Dezember 2012
Promising data presented at ASH support continued development of multiple investigational medicines and demonstrate breadth of Roche's robust hematology pipeline
Roche announced encouraging data from four investigational medicines at the 2012 American Society of Hematology (ASH) Annual ... mehr

08. Dezember 2012
Roche reports positive studies of MabThera given by subcutaneous injection
Pivotal study data presented at ASH shows that subcutaneous administration enables the delivery of MabThera over approximately ... mehr

08. Dezember 2012
Roche's Perjeta significantly extends survival in people with HER2-positive metastatic breast cancer
Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta ... mehr

07. Dezember 2012
Changes in Roche Board of Directors
At its December meeting, the Board of Directors (BoD) of Roche Holding recommended proposals for approval by the AGM, scheduled ... mehr

29. November 2012
Roche's Zelboraf named Best New Drug at the 2012 Scrip Awards
Roche announced today that its cancer drug Zelboraf (vemurafenib) won the Best New Drug award at the 2012 Scrip Awards ceremony ... mehr

17. November 2012
Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy
Roche today announced results from the positive phase III AVAglio study. The study showed Avastin (bevacizumab) in combination ... mehr

16. November 2012
Roche receives positive opinion from European Medicines Agency for Avastin based treatment beyond first progression in people with advanced colorectal cancer
The continued use of Avastin based therapy beyond first progression in metastatic colorectal cancer patients leads to survival ... mehr

07. November 2012
FDA grants Roche's trastuzumab emtansine (T-DM1) Priority Review for HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License ... mehr

05. November 2012
Roche`s aleglitazar renal safety study AleNephro meets primary endpoint
Roche today announced data from the Phase II AleNephro study which showed that in patients with moderate renal impairment ... mehr

31. Oktober 2012
Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer
Roche announced today that the European Commission (EC) has approved Avastin (bevacizumab) in combination with standard chemotherapy ... mehr

16. Oktober 2012
Roche Group posts strong sales growth in the third quarter
Group sales rise 4% at CER to 33.7 billion Swiss francs (+7% in Swiss francs) in the first nine months; Cancer medicines ... mehr

15. Oktober 2012
FDA approves expanded indication for ACTEMRA in Rheumatoid Arthritis
Roche today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) ... mehr

09. Oktober 2012
Reminder: Invitation to Roche's Third Quarter Sales 2012 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Tuesday, ... mehr

05. Oktober 2012
Anti-Cancer Agent “Avastin” Application for Approval of Additional Indication of Ovarian Cancer
Please find attached a press release by Chugai. mehr

02. Oktober 2012
Reminder - Roche conference call for investors and analysts from ESMO 2012
Tuesday, 2 October 2012, Vienna, Austria. Highlights to be discussed: T-DM1: Updated overall survival results from EMILIA, ... mehr

01. Oktober 2012
Roche'’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer
Roche today announced updated survival results from the Phase III EMILIA study, which showed that people with previously treated ... mehr

01. Oktober 2012
Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer
Roche and the Breast International Group (BIG) today announced final results from the Phase III HERA trial, which confirmed ... mehr

24. September 2012
ESMO 2012: Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer
Roche today announced that data on thirteen of its investigational and approved products will be presented at the European ... mehr

21. September 2012
Roche's Avastin receives positive opinion from EU authority for the treatment of women with recurrent, platinum-sensitive ovarian cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the ... mehr

21. September 2012
Roche conference call for investors and analysts from ESMO 2012
We kindly invite investors and analysts to participate in a conference call that will be held during the ESMO congress from ... mehr

19. September 2012
Anti-Cancer Agent “Avastin” Application for Approval of Additional Indication of Recurrent Glioblastoma
Dear Investor, please find attached a press release by Chugai. mehr

18. September 2012
Invitation to Roche's Third Quarter Sales 2012 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Tuesday, ... mehr

13. September 2012
Roche leads healthcare sector in key sustainability index for fourth consecutive year
Roche announced today that it has been recognised as the most sustainable healthcare company globally in the Dow Jones Sustainability ... mehr

05. September 2012
Roche committed to innovation and growth
Personalised healthcare leadership and world-class pipeline presented at investor conference mehr

28. August 2012
Changes to the Roche Corporate Executive Committee
Roche announced today that Daniel O’Day, currently Chief Operating Officer (COO) of Roche Diagnostics has been appointed ... mehr

27. August 2012
New data from Phase III EMILIA study showed Roche's trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer
Pivotal study met co-primary efficacy endpoint of overall survival. Roche today announced updated results from the Phase III ... mehr

13. August 2012
FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Roche today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) ... mehr

10. August 2012
Roche study showed that adding Avastin to radiation and chemotherapy significantly extended the time people with an aggressive form of brain cancer lived without their disease worsening
The Phase III AVAglio study met its co-primary endpoint of significantly improving progression-free survival in people with ... mehr

27. Juli 2012
FDA advisory committee unanimously recommends approval of Lucentis for treatment of diabetic macular edema (DME)
Roche announced that the U.S. Food & Drug Administration (FDA) Dermatologic & Ophthalmic Drugs Advisory Committee ... mehr

27. Juli 2012
Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis
Roche today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous ... mehr

26. Juli 2012
Full reconciliation of Chugai half-year 2012 results into IFRS
Results of Chugai as consolidated by the Roche Group mehr

26. Juli 2012
FDA clears Roche's vitamin D laboratory test
Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated ... mehr

26. Juli 2012
Roche posts strong operating first-half results; on track to meet 2012 guidance
Roche posts strong operating first-half results; on track to meet 2012 guidance mehr

19. Juli 2012
Reminder: Invitation to Roche's Half Year Results for 2012
Roche will publish its Half Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 26th July, 2012 mehr

19. Juli 2012
FDA clears Accu-Chek Combo system - Roche's new interactive insulin pump system for people with diabetes
The system will be available in the United States in the second half of 2012. Roche announced today that it has received clearance ... mehr

27. Juni 2012
Invitation to Roche's Half Year Results for 2012
Roche will publish its Half Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 26th July, 2012. mehr

26. Juni 2012
Roche to streamline research and development activities
Roche site in Nutley (New Jersey, USA) to be closed – respective R&D activities to be consolidated in Switzerland ... mehr

26. Juni 2012
Anti-Cancer Agent 'Tarceva', Application for Approval of Additional Indication of Non-Small Cell Lung Cancer (First Line Therapy)
Please find attached a press release by Chugai mehr

22. Juni 2012
New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta
Roche announced today that people with HER-2 positive metastatic breast cancer (mBC) lived significantly longer (overall survival) ... mehr

19. Juni 2012
Roche and Seaside Therapeutics Announce Landmark Alliance to Advance Novel Treatments for Fragile X Syndrome and Autism Spectrum Disorders
Roche and Seaside Therapeutics announced today that they have entered into a collaboration to develop disease modifying treatments ... mehr

11. Juni 2012
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
New personalised medicine gives people with aggressive form of breast cancer more time without their disease worsening. Roche ... mehr

06. Juni 2012
Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Roche today announced data from the ADACTA study which showed that adult rheumatoid arthritis (RA) patients who received RoACTEMRA ... mehr

03. Juni 2012
Roche data showed that people with metastatic colorectal cancer lived longer when they continued on Avastin plus chemotherapy
Roche today announced results from ML18147, a phase III study in metastatic colorectal cancer (mCRC) that evaluated Avastin ... mehr

03. Juni 2012
Roche's targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III trial
Roche today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint, of a significant ... mehr

02. Juni 2012
Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half
Roche today announced results from AURELIA, a phase III study that evaluated treatment with Avastin (bevacizumab) in combination ... mehr

01. Juni 2012
Reminder: Roche conference call for investors and analysts from EULAR 2012
ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with ... mehr

30. Mai 2012
Reminder: Roche Analyst Event at ASCO 2012
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products ... mehr

25. Mai 2012
Roche Analyst Event at ASCO 2012
Analyst briefing on data presented at ASCO: Sunday, 3rd June 2012 mehr

25. Mai 2012
New Drug Application Filed for Anti-Cancer Agent 'Pertuzumab' for the Treatment of HER2-Positive Metastatic or Recurrent Breast Cancer
Please find attached a press release by Chugai mehr

24. Mai 2012
Invitation Roche Investor Day 2012
Dr Severin Schwan (CEO Roche group) and the Investor Relations team would like to invite you to the Roche Investor Day to ... mehr

16. Mai 2012
Roche will report new data on important progress for people with advanced cancers at ASCO 2012
Roche today announced that the company will present important new data from studies of several of its cancer medicines at ... mehr

10. Mai 2012
Roche conference call for investors and analysts from EULAR 2012
ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with ... mehr

07. Mai 2012
Roche provides update on Phase III study of dalcetrapib
Roche today announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III ... mehr

03. Mai 2012
Roche Analyst Event at ASCO 2012
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products ... mehr

03. Mai 2012
Roche reports positive study of RoACTEMRA given by subcutaneous injection
Roche today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) ... mehr

19. April 2012
Roche reports high rates of sustained viral clearance with investigational hepatitis C treatment danoprevir
Roche today announced data showing high SVR12 rates (maintaining undetectable viral levels 12 weeks after stopping treatment) ... mehr

18. April 2012
Roche decides not to extend its tender offer for Illumina, Inc.
Roche released the following statement based on preliminary estimates indicating the re-election of the incumbent directors ... mehr

12. April 2012
Roche issues statement regarding Illumina offer
Roche (SIX: RO, ROG; OTCQX: RHHBY) released the following statement regarding its pending offer for Illumina, Inc. (NASDAQ: ... mehr

12. April 2012
Roche on track for full-year targets - good sales growth in first quarter
Group sales rise 2% at CER (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss francs. Excluding Tamiflu, sales ... mehr

11. April 2012
Roche sends open letter to Illumina shareholders
Roche today sent an open letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to vote the GOLD proxy card for ... mehr

06. April 2012
Roche disappointed with ISS recommendation
Roche released the following statement in response to a report issued by Institutional Shareholder Services (“ISS”) ... mehr

04. April 2012
Roche sends second letter to Illumina shareholders
Roche today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into ... mehr

03. April 2012
Reminder: Invitation to Roche's First Quarter Sales 2012 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

03. April 2012
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
By not engaging with Roche, Illumina reinforces notion of an entrenched Board. Roche released the following statement in response ... mehr

30. März 2012
Roche's trastuzumab emtansine (T-DM1) showed positive Phase III results in HER2-positive metastatic breast cancer
Roche today announced topline results of EMILIA, the first randomised Phase III study of trastuzumab emtansine (T-DM1). mehr

29. März 2012
Roche increases offer price for Illumina shares to US$ 51.00 per share
Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. (NASDAQ: ... mehr

26. März 2012
Roche extends tender offer for Illumina
Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ... mehr

23. März 2012
Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion
Subcutaneous administration of Herceptin is less invasive and takes approximately 5 minutes instead of 30-90 minutes with ... mehr

20. März 2012
Roche files definitive proxy statement
Roche today announced that it filed its definitive proxy statement and sent a letter to shareholders of Illumina, Inc. (NASDAQ: ... mehr

13. März 2012
Roche receives request for additional information from the Federal Trade Commission
Roche announced today that it has received a request for additional information, often referred to as a “second request,” ... mehr

12. März 2012
Invitation to Roche's First Quarter Sales 2012 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2012 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

12. März 2012
Second Transnet-Phelophepa Healthcare Train inaugurated in South Africa
Roche doubles its support for unique project providing healthcare to reach 90,000 patients a year in rural South Africa. Today, ... mehr

06. März 2012
Roche Annual General Meeting 2012
Roche's Annual General Meeting, held today in Basel, approved all of the Board of Directors' proposals. The 755 ... mehr

02. März 2012
Roche's RoACTEMRA monotherapy showed superior improvement in rheumatoid arthritis signs and symptoms versus adalimumab monotherapy
Roche today announced that preliminary results from the ADACTA study (ADalimumab ACTemrA) showed that patients who received ... mehr

27. Februar 2012
Roche extends tender offer for Illumina
Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ... mehr

20. Februar 2012
Roche's Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer
First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live ... mehr

08. Februar 2012
FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License ... mehr

08. Februar 2012
Roche disappointed by the actions of Illumina, Inc.'s Board of Directors
Roche released the following statement in response to the announcement by Illumina, Inc. that its Board of Directors has recommended ... mehr

01. Februar 2012
Full reconciliation of Chugai 2011 results into IFRS
Following the publication of Chugai’s official 2011 results, Roche offers this investor update which reconciles these ... mehr

01. Februar 2012
Roche in 2011: Strong results and positive outlook
Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu; Significant foreign exchange impact of ... mehr

31. Januar 2012
Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting
Roche announced today that it has provided notice to Illumina, Inc. (NASDAQ: ILMN) that it will nominate a slate of highly ... mehr

30. Januar 2012
FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma
Roche today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults ... mehr

27. Januar 2012
Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash
Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals, life science tools and diagnostics, ... mehr

27. Januar 2012
Roche responds to adoption of shareholder rights plan by Illumina Board of Directors
Roche today responded to an announcement from Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has adopted a shareholder ... mehr

26. Januar 2012
Avastin-based regimen extends survival when continued beyond initial treatment in patients with metastatic colorectal cancer
First randomised phase III trial evaluating continued use of Avastin with chemotherapy after disease progression meets primary ... mehr

25. Januar 2012
Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics
Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. (NASDAQ:ILMN) for $44.50 per ... mehr

18. Januar 2012
Reminder: Invitation to Roche's Full Year Results for 2011
Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at ... mehr

11. Januar 2012
Roche receives clearance from the U.S. Food and Drug Administration for the new Accu-Chek Nano SmartView blood glucose monitoring system
Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Nano ... mehr

03. Januar 2012
Invitation to Roche's Full Year Results for 2011
Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at ... mehr